UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/534,208	11/02/2005	Lidia Elfstrand	05822.0323USWO	9970
23552 MERCHANT &	7590 04/28/200 & GOULD PC	EXAMINER		
P.O. BOX 2903			BASQUILL, SEAN M	
WIINNEAPOLI	MN 55402-0903		ART UNIT	PAPER NUMBER
			1612	
			MAIL DATE	DELIVERY MODE
			04/28/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

		Application No.	Applicant(s)			
Office Action Summary		10/534,208	ELFSTRAND ET AL.			
		Examiner	Art Unit			
		Sean Basquill	1612			
Period fo	The MAILING DATE of this communication a or Reply	ppears on the cover sheet with the	e correspondence address			
WHIC - Exter after - If NC - Failu Any (	ORTENED STATUTORY PERIOD FOR REPERIOD FOR REPERIOR IS LONGER, FROM THE MAILING asions of time may be available under the provisions of 37 CFR of SIX (6) MONTHS from the mailing date of this communication. It is period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by statutely preceived by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION IN 136(a). In no event, however, may a reply be d will apply and will expire SIX (6) MONTHS fructe, cause the application to become ABANDO	ON.  timely filed  om the mailing date of this communication.  NED (35 U.S.C. § 133).			
Status						
1)[\	Responsive to communication(s) filed on 18	February 2009				
•	Responsive to communication(s) filed on <u>18 February 2009</u> .  This action is <b>FINAL</b> .  2b) This action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
٥,١	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Dispositi	on of Claims					
- 4)⊠	Claim(s) <u>1-17</u> is/are pending in the application	in.				
•	4a) Of the above claim(s) is/are withdrawn from consideration.					
	5) Claim(s) is/are allowed.					
	6)⊠ Claim(s) <u>1-17</u> is/are rejected.					
	Claim(s) is/are objected to.					
	Claim(s) are subject to restriction and	or election requirement.				
	on Papers	1				
	•					
•	The specification is objected to by the Exami					
10)	The drawing(s) filed on is/are: a) a	•				
	Applicant may not request that any objection to the					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority ι	ınder 35 U.S.C. § 119					
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some color None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
2)  Notic 3)  Inform	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date 29 Sep 2008; 11 Mar 2009.	4) Interview Summa Paper No(s)/Mail 5) Notice of Informa 6) Other:				
•	•					

Application/Control Number: 10/534,208 Page 2

Art Unit: 1612

## **DETAILED ACTION**

## **Previous Rejections**

1. Applicants' arguments, filed 18 February 2009, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

## Claim Rejections - 35 USC § 103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

2. Claims 1-13 and 15-17 stand rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent 6,202,546 ("Scammell"), in view of U.S. Patent 3,689,290 ("Blackstock") as put forth in the previous action.

Applicants arguments have been fully considered but are deemed unpersuasive. While Scammell provides many examples incorporating the colostrum concentrate into liquid dairy products, Scammell additionally indicates the colostrum obtainable through their process may be incorporated into solid dairy products such as cheese formulations. Scammell, more properly speaking, is therefore directed to methods of providing colostrum-based immunotherapy via fortified dairy products. Because prior art is art for all that it expressly discloses and reasonably suggests to the ordinarily skilled artisan, MPEP § 2123, Scammell therefore suggests the desirability of incorporating colostrum into solids such as cheese formulations. Because

Application/Control Number: 10/534,208

Art Unit: 1612

Blackstock is also directed to cheese formulations, the ordinarily skilled artisan would clearly be motivated to incorporate the colostrum therapy disclosed by Scammell. Additionally, the examiner directed the applicants to the teaching of Blackstock concerning the particulate size, as pointed out in the previous action. Blackstock clearly invites the particle size optimization relied upon by the examiner via the express teaching that such particle size may be adjusted to a desired size and configuration, with the general condition of particles of between 12-100 mesh disclosed. Given this teaching, and absent any secondary indicia of nonobviousness, the rejection is proper.

Page 3

Applicants arguments that Scammell "teaches away from" the incorporation of colostrum into the cheese product of Blackstock are misplaced. For a reference to properly "teach away" from the combination of references, the art must render the prior art unsatisfactory for its intended purpose, change the principle of operation of a reference, or "criticize, discredit, or otherwise discourage the solution claimed," MPEP § 2145(X)(D). As described above, the disclosure of Scammell is more properly characterized as teaching the incorporation of immunotherapeutic colostrum into dairy products, such as the cheese product described by Blackstock. The disclosure of neither Scammell, nor Blackstock, nor the optimization of the particulate size advanced by the examiner, render the prior art unsatisfactory for its intended purpose, change the principle of operation of a reference, or criticize, discredit, or otherwise discourage the solution claimed.

3. Claims 1-17 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Scammell and Blackstock, as applied to Claims 1-13 and 15-17 above, and further in view of U.S. Patent 5,846,569 ("Anderson") as put forth in the previous action.

Applicants arguments have been fully considered but are deemed unpersuasive.

Applicants arguments concerning the combination of Scammell and Blackstock, as well as the optimization of the prior art particulate size, have been addressed by the examiner above. In addition, applicants comments concerning the beneficial effects of bovine colostrum for patients with gastrointestinal symptoms are considered irrelevant in view of the claims presented, which are directed to compositions, and not methods of treating gastrointestinal symptoms using bovine colostrum.

## Conclusion

No Claims stand allowable.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Application/Control Number: 10/534,208 Page 5

Art Unit: 1612

however, will the statutory period for reply expire later than SIX MONTHS from the mailing

date of this final action.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Sean Basquill whose telephone number is (571) 270-5862. The

examiner can normally be reached on Monday through Thursday, between 8AM and 6PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Frederick Krass can be reached on (571) 272-0580. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Sean Basquill

Art Unit 1612

/Frederick Krass/

Supervisory Patent Examiner, Art Unit 1612

Application/Control Number: 10/534,208

Page 6

Art Unit: 1612